How many drugs treat Acute maxillary sinusitis?

Drug Landscape tracks 8 marketed treatments for Acute maxillary sinusitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/acute-maxillary-sinusitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-11 · How we verify

Acute maxillary sinusitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acute maxillary sinusitis (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Acute maxillary sinusitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cefpodoxime Proxetil	CEFPODOXIME	Pfizer			2007-01-01
Levaquin	levofloxacin	Generic (originally Daiichi Sankyo/J&J)	Fluoroquinolone Antibacterial [EPC]	CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2	1996-12-20
Biaxin	clarithromycin	Generic (originally Abbott/AbbVie)	Macrolide Antimicrobial [EPC]	Potassium voltage-gated channel subfamily H member 2	1991-10-31
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Ceftin	CEFUROXIME AXETIL	GSK	Cephalosporin Antibacterial		1987-01-01
Zinacef	CEFUROXIME	GSK	Cephalosporin Antibacterial	Carbonic anhydrase 2	1983-01-01
Ofloxacine	Ofloxacine	Assistance Publique - Hôpitaux de Paris		Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1
Ciprofloxacine	Ciprofloxacine	Poitiers University Hospital		DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 3 drugs in Acute maxillary sinusitis
GSK · 2 drugs in Acute maxillary sinusitis
Bayer AG · 1 drug in Acute maxillary sinusitis
Generic (originally Abbott/AbbVie) · 1 drug in Acute maxillary sinusitis
Generic (originally Daiichi Sankyo/J&J) · 1 drug in Acute maxillary sinusitis
Pfizer · 1 drug in Acute maxillary sinusitis
Poitiers University Hospital · 1 drug in Acute maxillary sinusitis
Assistance Publique - Hôpitaux de Paris · 1 drug in Acute maxillary sinusitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Acute maxillary sinusitis:

Cite this brief

Drug Landscape (2026). Acute maxillary sinusitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/acute-maxillary-sinusitis. Accessed 2026-06-11.

Acute maxillary sinusitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing